AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33028479 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Number of subjects: 94
Study 33028479 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 94
Study 34922872 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC guidance
Number of subjects: 601
Study 34922872 — intervention group
Group type: COMPARATOR
Intervention: PCE guidance
Number of subjects: 601
Study 33948095 — intervention group
Group type: EXPERIMENTAL
Intervention: Romanian deadlift
Number of subjects: 15
Study 33948095 — intervention group
Group type: EXPERIMENTAL
Intervention: Roman chair back extension
Number of subjects: 15
Study 33948095 — intervention group
Group type: COMPARATOR
Intervention: Seated machine back extension
Number of subjects: 15
Study 33948095 — intervention group
Group type: EXPERIMENTAL
Intervention: All three exercises
Number of subjects: 15
Study 33023647 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study 36141627 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 servings/day of nutritionally complete ONS powder (Fresubin® Powder), 600 kcal, 22.4 g protein for 12 weeks
Number of subjects: 88
Study 36141627 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 88
Study 32000680 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration method
Number of subjects: 88
Study 32000680 — intervention group
Group type: COMPARATOR
Intervention: Conventional popping method
Number of subjects: 88
Study 33417683 — intervention group
Group type: EXPERIMENTAL
Intervention: SMC+AZ
Number of subjects: 30977
Study 33417683 — intervention group
Group type: COMPARATOR
Intervention: SMC+placebo
Number of subjects: 30977
Study 35995721 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho-k lenses with compression factor of 0.75 D
Number of subjects: 75
Study 35995721 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho-k lenses with compression factor of 1.75 D
Number of subjects: 75
Study 35995721 — intervention group
Group type: COMPARATOR
Intervention: Control group (single-vision spectacles)
Number of subjects: 75
Study 34193499 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference-based smoking cessation intervention (STOP) using various nicotine substitutes (patches, inhalers, gum, tablets, etc.) and/or electronic cigarettes delivered free of charge.
Number of subjects: 0
Study 34193499 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 0
Study 35598456 — intervention group
Group type: EXPERIMENTAL
Intervention: Online education intervention (six hours of education delivered online over three sessions across three weeks)
Number of subjects: 89
Study 35598456 — intervention group
Group type: EXPERIMENTAL
Intervention: Online education intervention
Number of subjects: 89
Study 35598456 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 89
Study 33264568 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology exercises for 8 weeks
Number of subjects: 108
Study 33264568 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness and writing about current life events (Control)
Number of subjects: 108
Study 33264568 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology exercises
Number of subjects: 108
Study 34021843 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiation with cisplatin (CCRT)
Number of subjects: 508
Study 34021843 — intervention group
Group type: COMPARATOR
Intervention: Nimotuzumab-cisplatin (NCRT)
Number of subjects: 508
Study 32191600 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine supplementation (0.06 g/kg/meal; n = 10)
Number of subjects: 20
Study 32191600 — intervention group
Group type: COMPARATOR
Intervention: Alanine control (0.06 g/kg/meal; n = 10)
Number of subjects: 20
Study 32191600 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine supplementation
Number of subjects: 20
Study 36158131 — intervention group
Group type: EXPERIMENTAL
Intervention: TPVB (thoracic paravertebral block) with 15 mL of 0.375% ropivacaine hydrochloride
Number of subjects: 108
Study 36158131 — intervention group
Group type: EXPERIMENTAL
Intervention: TPVB (thoracic paravertebral block)
Number of subjects: 108
Study 36158131 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 108
Study 33957663 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile meditation app for 30 days
Number of subjects: 101
Study 33957663 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 101
Study 32324592 — intervention group
Group type: EXPERIMENTAL
Intervention: erlotinib (Erlo) + bevacizumab (Bev)
Number of subjects: 0
Study 32324592 — intervention group
Group type: EXPERIMENTAL
Intervention: osimertinib (Osi)
Number of subjects: 0
Study 32324592 — intervention group
Group type: EXPERIMENTAL
Intervention: afatinib (Afa)
Number of subjects: 0
Study 32324592 — intervention group
Group type: EXPERIMENTAL
Intervention: immunotherapy (IT) + anti-VEGFR (aVEGFR) + platinum-based therapy (Plat)
Number of subjects: 0
Study 32324592 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR-TKI (ET) + aVEGFR
Number of subjects: 0
Study 32324592 — intervention group
Group type: EXPERIMENTAL
Intervention: cetuximab (Cet) + Bev + Plat
Number of subjects: 0
Study 32324592 — intervention group
Group type: EXPERIMENTAL
Intervention: cilengitide (Cil) + Cet + Plat
Number of subjects: 0
Study 32324592 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR-TKI (ET) + aVEGFR + Plat
Number of subjects: 0
Study 32324592 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR-TKI (ET) + Plat
Number of subjects: 0
Study 32324592 — intervention group
Group type: EXPERIMENTAL
Intervention: third-generation EGFR-TKI (3rd ET)
Number of subjects: 0
Study 32324592 — intervention group
Group type: EXPERIMENTAL
Intervention: gefitinib (Gef) + pemetrexed (Peme)
Number of subjects: 0
Study 32324592 — intervention group
Group type: EXPERIMENTAL
Intervention: erlotinib (Erlo) + bevacizumab (Bev) + Plat
Number of subjects: 0
Study 32324592 — intervention group
Group type: EXPERIMENTAL
Intervention: immunotherapy (IT) + aVEGFR + Plat
Number of subjects: 0
Study 32798360 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 122
Study 32798360 — intervention group
Group type: COMPARATOR
Intervention: Other oral hypoglycaemic agents, insulin or statins
Number of subjects: 122
Study 34698901 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg single oral dose
Number of subjects: 11
Study 34698901 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 50 mg intravenous (IV) dose
Number of subjects: 11
Study 34698901 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral and IV lorlatinib
Number of subjects: 11
Study 33743185 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive digital story intervention
Number of subjects: 238
Study 33743185 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 238
Study 34383179 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg BID)
Number of subjects: 151
Study 34383179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 32493318 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention lectures with written take-home messages (THMs)
Number of subjects: 73
Study 32493318 — intervention group
Group type: COMPARATOR
Intervention: Control lectures without written take-home messages (THMs)
Number of subjects: 73
Study 33407776 — intervention group
Group type: EXPERIMENTAL
Intervention: ICan intervention (Internet-based cannabis reduction intervention)
Number of subjects: 0
Study 33407776 — intervention group
Group type: COMPARATOR
Intervention: Four online modules of educational information on cannabis (Control)
Number of subjects: 0
Study 32635768 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic treatment in black patients
Number of subjects: 721
Study 32635768 — intervention group
Group type: COMPARATOR
Intervention: Diuretic treatment in nonblack patients
Number of subjects: 721
Study 35939311 — intervention group
Group type: EXPERIMENTAL
Intervention: eTRE+ER (8-hour eating window from 7:00 to 15:00)
Number of subjects: 90
Study 35939311 — intervention group
Group type: COMPARATOR
Intervention: CON+ER (≥12-hour eating window)
Number of subjects: 90
Study 34227693 — intervention group
Group type: EXPERIMENTAL
Intervention: Online interprofessional education applied learning activity (IPE ALA)
Number of subjects: 86
Study 34227693 — intervention group
Group type: EXPERIMENTAL
Intervention: ISVS-9A (modified)
Number of subjects: 86
Study 34227693 — intervention group
Group type: EXPERIMENTAL
Intervention: ISVS-9B (modified)
Number of subjects: 86
Study 35499850 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 mg/kg/d fenfluramine
Number of subjects: 263
Study 35499850 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg/d fenfluramine
Number of subjects: 263
Study 35499850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 32858063 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of vitamin A, vitamin B6, vitamin C, folate, β-carotene, lutein and zeaxanthin, magnesium, copper, and alcohol (quintiles 4 or 5 vs. 1)
Number of subjects: 14135
Study 32858063 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of saturated fatty acid, monounsaturated fatty acid, and oleic acid (quintiles 4 or 5 vs. 1)
Number of subjects: 14135
Study 32858063 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of vitamin A, vitamin B6, β-carotene, lutein and zeaxanthin, magnesium, copper, docosahexaenoic acid, omega-3 fatty acid, and alcohol (quintiles 4 or 5 vs. 1)
Number of subjects: 14135
Study 32858063 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of 12 nutrients (separate analyses)
Number of subjects: 14135
Study 33369488 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of preoperative antibiotics
Number of subjects: 123
Study 33369488 — intervention group
Group type: COMPARATOR
Intervention: 2 days of preoperative antibiotics
Number of subjects: 123
Study 36223712 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Mg treatment (mean dose 205.58 mg/day, range 77.25 to 389.55 mg/day)
Number of subjects: 240
Study 36223712 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm
Number of subjects: 240
Study 36223712 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Mg treatment
Number of subjects: 240
Study 33341417 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral regurgitation fraction (MRF) ≥30%
Number of subjects: 441
Study 33341417 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral regurgitation fraction (MRF) ≥30% among patients with scar
Number of subjects: 441
Study 33341417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate scar burden
Number of subjects: 441
Study 32576350 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA mode ventilation
Number of subjects: 16
Study 32576350 — intervention group
Group type: COMPARATOR
Intervention: PSV mode ventilation
Number of subjects: 16
Study 35461264 — intervention group
Group type: EXPERIMENTAL
Intervention: INTELLiVENT‐ASV (automated ventilation)
Number of subjects: 1200
Study 35461264 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (not automated)
Number of subjects: 1200
Study 33705891 — intervention group
Group type: EXPERIMENTAL
Intervention: Real AAT
Number of subjects: 56
Study 33705891 — intervention group
Group type: COMPARATOR
Intervention: Sham AAT
Number of subjects: 56
Study 32369689 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART (Stress Management and Resiliency Training)
Number of subjects: 23
Study 35772479 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported Physical Activity (PA)
Number of subjects: 122
Study 32166907 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII + CGM
Number of subjects: 28
Study 32166907 — intervention group
Group type: COMPARATOR
Intervention: MDI + SMBG
Number of subjects: 28
Study 34941423 — intervention group
Group type: EXPERIMENTAL
Intervention: molnupiravir (800 mg)
Number of subjects: 202
Study 34941423 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 202
Study 34941423 — intervention group
Group type: EXPERIMENTAL
Intervention: molnupiravir (400 or 800 mg)
Number of subjects: 202
Study 33074143 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 31
Study 33074143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 35050343 — intervention group
Group type: EXPERIMENTAL
Intervention: AI system for subtask 1 (prioritized problem list)
Number of subjects: 967
Study 35050343 — intervention group
Group type: EXPERIMENTAL
Intervention: AI system for subtask 2 (treatment planning)
Number of subjects: 967
Study 35050343 — intervention group
Group type: COMPARATOR
Intervention: Peer group orthodontists (control)
Number of subjects: 967
Study 33788437 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding
Number of subjects: 98
Study 33788437 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 98
Study 35971840 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4744
Study 34682534 — intervention group
Group type: EXPERIMENTAL
Intervention: Taekwondo training (5 times per week for 16 weeks)
Number of subjects: 24
Study 34682534 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 32877157 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine combined with midazolam nasal drops
Number of subjects: 80
Study 32877157 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study 35337289 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (20 mg/kg)
Number of subjects: 449
Study 35337289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study 33479782 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led healthy lifestyle intervention
Number of subjects: 28
Study 33479782 — intervention group
Group type: COMPARATOR
Intervention: Non-peer provider support
Number of subjects: 28
Study 35308069 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic L-arginine supplementation (5 g, twice a day for 13 days)
Number of subjects: 16
Study 35308069 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute L-arginine supplementation (5 g)
Number of subjects: 16
Study 35308069 — intervention group
Group type: COMPARATOR
Intervention: Chronic placebo supplementation (5.5 g dextrin, twice a day for 13 days)
Number of subjects: 16
Study 35308069 — intervention group
Group type: COMPARATOR
Intervention: Acute placebo supplementation (5.5 g dextrin)
Number of subjects: 16
Study 33530512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 19
Study 33530512 — intervention group
Group type: COMPARATOR
Intervention: Western diet (WD)
Number of subjects: 19
Study 33530512 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (KD and WD)
Number of subjects: 19
Study 33033029 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated health service provision for HIV infection, DM, and hypertension
Number of subjects: 0
Study 33033029 — intervention group
Group type: COMPARATOR
Intervention: Current stand-alone vertical care
Number of subjects: 0
Study 36442064 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical masks
Number of subjects: 1009
Study 36442064 — intervention group
Group type: COMPARATOR
Intervention: N95 respirators
Number of subjects: 1009
Study 36442064 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical masks (Canada)
Number of subjects: 1009
Study 36442064 — intervention group
Group type: COMPARATOR
Intervention: N95 respirators (Canada)
Number of subjects: 1009
Study 36442064 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical masks (Israel)
Number of subjects: 1009
Study 36442064 — intervention group
Group type: COMPARATOR
Intervention: N95 respirators (Israel)
Number of subjects: 1009
Study 36442064 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical masks (Pakistan)
Number of subjects: 1009
Study 36442064 — intervention group
Group type: COMPARATOR
Intervention: N95 respirators (Pakistan)
Number of subjects: 1009
Study 36442064 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical masks (Egypt)
Number of subjects: 1009
Study 36442064 — intervention group
Group type: COMPARATOR
Intervention: N95 respirators (Egypt)
Number of subjects: 1009
Study 33296278 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 12
Study 33296278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 34864156 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorectal function testing (ARM and BET)
Number of subjects: 0
Study 34864156 — intervention group
Group type: COMPARATOR
Intervention: Empirical dietary/lifestyle interventions and laxative therapy
Number of subjects: 0
Study 34864156 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic evaluation
Number of subjects: 0
Study 34864156 — intervention group
Group type: EXPERIMENTAL
Intervention: General treatment options
Number of subjects: 0
Study 34304881 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumen-protected blend of B vitamins and choline (RPBV)
Number of subjects: 61
Study 34304881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprotected blend of B vitamins and choline and fat (UPBV)
Number of subjects: 61
Study 34304881 — intervention group
Group type: COMPARATOR
Intervention: Fat only (CTRL)
Number of subjects: 61
Study 34076977 — intervention group
Group type: EXPERIMENTAL
Intervention: LncRNA TUSC8 overexpression
Number of subjects: 45
Study 34076977 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin treatment (0 μM, 2 μM, 4 μM, 8 μM, 16 μM)
Number of subjects: 45
Study 34076977 — intervention group
Group type: EXPERIMENTAL
Intervention: LncRNA TUSC8
Number of subjects: 45
Study 33137100 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide mass drug administration (MDA) with albendazole targeting eligible individuals of all ages (20 clusters)
Number of subjects: 6000
Study 33137100 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care deworming program targeting children
Number of subjects: 6000
Study 616777178 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular lumbar facet joint pulsed radiofrequency
Number of subjects: 0
Study 616777178 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular lumbar facet joint corticosteroid injection
Number of subjects: 0
Study 33992236 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip abductor strengthening exercises
Number of subjects: 24
Study 33992236 — intervention group
Group type: COMPARATOR
Intervention: Stabilization exercises
Number of subjects: 24
Study 32103254 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and Brief Intervention (SBI)
Number of subjects: 130
Study 32103254 — intervention group
Group type: COMPARATOR
Intervention: General advice (Control)
Number of subjects: 130
Study 33038899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling (whole body hypothermia)
Number of subjects: 109
Study 33038899 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (control group)
Number of subjects: 109
Study 33038899 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher RANTES levels
Number of subjects: 109
Study 33038899 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher day 7 MCP-1 levels
Number of subjects: 109
Study 33038899 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-α levels
Number of subjects: 109
Study 32658147 — intervention group
Group type: EXPERIMENTAL
Intervention: WebMAP Mobile app and WebMAP parent website
Number of subjects: 143
Study 32658147 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 143
Study 32658147 — intervention group
Group type: EXPERIMENTAL
Intervention: WebMAP Mobile app (greater engagement)
Number of subjects: 143
Study 34182373 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 105
Study 34182373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 34182373 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal condition
Number of subjects: 105
Study 34182373 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum smoking
Number of subjects: 105
Study 34182373 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 105
Study 32651013 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping for 60 seconds
Number of subjects: 105
Study 32651013 — intervention group
Group type: COMPARATOR
Intervention: Delayed cord clamping for 30 seconds
Number of subjects: 105
Study 36211709 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation-related thrombosis
Number of subjects: 188
Study 36211709 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial thrombosis
Number of subjects: 188
Study 36211709 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 188
Study 36211709 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-4
Number of subjects: 188
Study 36211709 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-6
Number of subjects: 188
Study 36211709 — intervention group
Group type: COMPARATOR
Intervention: E-selectin
Number of subjects: 188
Study 32045942 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronavigated rTMS (1 Hz)
Number of subjects: 20
Study 32045942 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 36484235 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital weight-loss intervention with coaching
Number of subjects: 161
Study 36484235 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital weight-loss intervention without coaching
Number of subjects: 161
Study 36484235 — intervention group
Group type: COMPARATOR
Intervention: In-person multidisciplinary obesity intervention
Number of subjects: 161
Study 34188108 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent users of SRIs
Number of subjects: 335794
Study 34188108 — intervention group
Group type: EXPERIMENTAL
Intervention: Former users of SRIs
Number of subjects: 335794
Study 34188108 — intervention group
Group type: COMPARATOR
Intervention: Non-users of SRIs
Number of subjects: 335794
Study 33055113 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-blood cardioplegia
Number of subjects: 0
Study 33055113 — intervention group
Group type: COMPARATOR
Intervention: Cold-blood cardioplegia
Number of subjects: 0